OUR DISCOVERY ENGINE

Our team of proven drug hunters is focused on a singular mission: Discovering the next generation of therapeutics for patients with endocrine diseases and related tumors. To leverage our capabilities and collective knowledge of the endocrine system and in G-protein coupled receptor (GPCR) pharmacology, we have organized our discovery team into three focus areas: endocrine disease, metabolic disease, and targeted therapeutics.

Endocrine disease

Since our inception more than 15 years ago, Crinetics has focused on developing innovative nonpeptide drug candidates that target specific GPCRs to modulate endocrine pathways for the benefit of patients. This research led to the approval of PALSONIFY (paltusotine) as the first once-daily, oral therapy approved by the FDA to treat adults with acromegaly in the United States.

Metabolic disease

Metabolic disorders, such as diabetes and obesity, impact the lives of hundreds of millions of people across the globe. Their effects on patients are significant and varied. Many of these disorders are a result of the dysregulation of key metabolic hormones (insulin, glucagon, glucagon-like peptide-1, and gastric inhibitory polypetide, among others). Crinetics’ understanding of these hormonal pathways and the GPCRs that control them, coupled with our skills in developing nonpeptides with specific pharmacologies, guides us in designing new molecules with the chance to improve the lives of these patients.

Targeted therapies

Crinetics’ GPCR drug discovery capabilities enable us to pioneer new approaches that leverage endocrine receptors to selectively deliver specific payloads to tumors and other tissues of interest. Our efforts in oncology began with developing nonpeptide, GPCR-targeted radioligands for the imaging and treatment of a broad range of endocrine receptor-driven cancers, ultimately leading to the formation of Radionetics Oncology in 2021. Following that, we continued to explore this concept of using nonpeptide ligands to target endocrine GPCRs relevant to oncology, but with nonradioactive payloads. Our continued dedication to this concept has led to our latest novel development program that is exploring a new modality known as nonpeptide drug conjugates (NDCs).

Exploring new frontiers with our science to expand patient reach

Our in-house R&D team of proven drug hunters develops transformative novel molecules with a focus on the endocrine system and GPCRs. Our pipeline is purposefully created to deliver innovative therapies.

See our pipeline